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Abstract
The ICRP has published two biokinetic models providing a basis for radiation dose assessment due to
radionuclides incorporated inside the gastrointestinal tract. These models are a sufficient tool to assess
the committed dose equivalent for occupational exposures to workers assuming normal anatomy. The
colostomy is becoming a more prevalent procedure. A colostomy permanently or temporarily bypasses
a portion of colon to allow rest and healing. There are four different colostomies; ascending, transverse,
descending and sigmoid and an ileostomy. As a patient’s strength returns, they can return to normal
daily activities, including returning to work. Therefore, as an ostomy patient returns to the workforce
handling radioactive material, the potential for exposure to the radioactive material for these workers
increases. The aim of this project is to determined whether or not an additional risk exists for these
workers and if additional limitations should be placed on ostomy patients handling uranium. In order to
determine if an additional risk exists two pathways are considered, ingestion and injection. Injection is a
unique pathway for this work and is defined as radioactive material entering through the stoma. As part
of the injection scenario as well as in the event contamination occurs, the dose per hou to the stoma
was also determined. Using modified ICRP 30 gastrointestinal models and ICRP 100 HATM models to
reflect the anatomy changes for each procedure, the committed dose equivalent (CDE) and committed
effective dose equivalent (CEDE) was determined for each procedure. In addition, using the more
limiting value between the CDE and CEDE annual limit, the annual limit on intake (ALI) was determined.
Based on a decrease in CDE values within the alimentary tract for each procedure and the determination
the ALIs were either equivalent or orders of magnitude greater than the current ICRP ALI values no
additional risk exists. Finally, based on the dose per hour resulting from stoma contamination, the
chemical hazards were determined to be of greater concern than the radiological. Therefore, no
additional guidance is needed for ostomy patients working with uranium.
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Key Terms
Annual Limit on Intake
The activity of radionuclide, when taken alone, would irradiate a person to the limit set for
occupational exposure [1].
Committed Dose Equivalent (HT,50)
The total dose equivalent in an organ or tissue after intake of a radionuclide into the body, 50
years for adults and 70 years for children [1].
Committed Effective Dose Equivalent
The committed dose equivalent weighted by the appropriate tissue weighting factor [1].
Equivalent dose
The absorbed dose multiplied by the appropriate quality factor [1].
Effective dose
The equivalent dose multiplied by the appropriate tissue weighting factor for a specified tissue
Linear Energy Transfer
The amount of energy transferred by radiation to a medium per unit distance
Tissue Weighting Factors
The ratio of the stochastic risk arising from tissue T to the risk when the whole body is uniformly
irradiated. Table 1 displays the tissue weighting factors from ICRP 26, ICRP 60, and ICRP 103
[2][3][4].

xii

Table 1: Tissue weighting factors from ICRP 26, ICRP 60, and ICRP 103
Tissue Weighting Factor
Tissue or Organ
ICRP 26 (1977)
ICRP 60 (1990)
ICRP 103 (2007)
Bone Marrow (red)
0.12
0.12
0.12
Breast
0.15
0.05
0.12
Lung
0.12
0.12
0.12
Stomach
0.12
0.12
Colon
0.12
0.12
Gonads
0.25
0.20
0.08
Thyroid
0.03
0.05
0.04
Bladder
0.05
0.04
Liver
0.05
0.04
Esophagus
0.05
0.04
Bone Surface
0.03
0.01
0.01
Skin
0.01
0.01
Salivary Glands
0.01
Brain
0.01
Remainder
0.30
0.05
0.12
Quality Factor/Radiation Weighting Factor
The modifying factor, dependent on the collision stopping power for charged particles, that is
used to determine equivalent dose from absorbed dose. This value is 20 for alpha particles and 1
for electrons [1].
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1.0 Introduction
The ICRP has published several different biokinetic models providing a basis for radiation dose
assessment due to radionuclides incorporated inside the human body. These models are sufficient tools
to assess the committed dose equivalent for occupational exposures to workers assuming normal
anatomy. A growing number of people have had a surgical procedure to remove either part of their
intestine or bypass a portion of their intestine. More specifically, these procedures include four
different colostomies, ascending, transverse, descending and sigmoid and an ileostomy. Surgery may be
required for various reasons including infection of the abdomen, injury to the colon or rectum, partial or
total blockage of the large bowel, or rectal or colon cancer. Furthermore, a colostomy may be
temporary or permanent depending on the extent of injury or disease. As a patient’s strength returns
they can return to normal daily activities, including returning to work. In general, an ostomy patient is
not limited in the job they can perform when they return [5]. Therefore, as an ostomy patient returning
to the workforce handling radioactive material, the potential for exposure to the radioactive material for
these workers increases.

The ICRP models for the GI tract assumes a pathway through unmodified organs and tissues and does
not take procedures such as these into consideration. In addition, there is no guidance from the Nuclear
Regulatory Commission (NRC) regarding restrictions on these workers, other than general guidance
regarding open wound and potential injection risks. The NRC states intake through wounds and skin
contamination must be evaluated and accounted for, when practical [1]. Therefore, it should be
determined whether or not an additional risk exists for these workers, and if an increased risk does
exist, what precautions need to be taken. This could include restrictions on the worker’s potential
exposure to radioactive material to the development of guidance in case of contamination of the stoma,
including the evaluation of what actions may be necessary to limit dose to the stoma and intestine itself.
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To examine the potential risk for a worker with an ostomy, biokinetic models will be modified to reflect
the new anatomy and estimate the dose to a worker with an ostomy following exposure to uranium. To
determine the internal dose for workers dealing with uranium who have undergone an operation on
their GI tract, the ICRP 30 and ICRP 100 biokinetic models can be modified to reflect the anatomical
changes made by each surgery. Using the modified models, the dose to each organ can be determined
as well as the total effective dose. The modified models will be used to investigate two different
pathways, ingestion and injection. Injection is a unique pathway proposed in this work for workers with
an ostomy. Injection refers to the instantaneous injection of material through the stoma. While
inhalation is also a pathway, it is not considered due to the small fraction of material transferred to the
gastrointestinal tract from the inhalation pathway. By looking at the NRC reported annual limit of intake
(ALI) for uranium, it can be determine whether or not a worker needs further limitations when working
with uranium.

2

2.0 Background

2.1 Internal Dosimetry
Biokinetic models for internal exposure are used to determine the number of transformations occurring
within an organ or tissue during a given period of time by determining the activity as a function of time
in each source region. This time usually ranges from 50 years for adults and 70 years for children [2]. The
model is used to calculate the number of transformations occurring in each region taking into account
the energies and yields of all emissions. Knowing the number of decays occurring in each organ and the
energy deposited, the committed dose equivalent in sievert can be calculated.

2.2 Dosimetry Principles
To evaluate the dose to target tissues, the committed equivalent dose, HT, is determined. The
committed equivalent dose is determined by the number of nuclear transformations of a radionuclide
within the source region, S, over a given period after intake of the radionuclide. In general, the period of
time is 50 years for adults. In addition, HT is determined by the energy absorbed per mass in the target
tissue, which is modified by the radiation weighting. The radiation weighting factor is dependent upon
the type of radiation emitted per nuclear transformation. The committed equivalent dose, HT, in the
target tissue T can be expressed by Equation 1 [1].

𝐻𝑇 = 𝑐𝑈𝑠 𝑆𝐸𝐸(𝑇 ← 𝑆)
Where Us is the number of transformations of a radionuclide 50 years after intake, 𝑆𝐸𝐸(𝑇 ← 𝑆) is the
specific effective energy per nuclear transformation in region S for a radionuclide and c taken to be
1.6x10-13, the number of joules in one MeV, assuming SEE is in MeV per unit mass [1].
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(1)

For each radionuclide in the decay chain, the specific effective energy (SEE) at age t takes into account
the contribution from each radiation emitted. This is also weighted by the appropriate radiation
weighting factor. The SEE can be determined by the following equation [1]
∞

𝑆𝐸𝐸(𝑇 ← 𝑆)𝑖 =

∑ 𝑤𝑅,𝑖 𝑌𝑖 𝐸𝑖 𝐴𝐹(𝑇←𝑆,𝐸𝑖 ,𝑡)+𝑤𝑅,𝛽 ∫0 𝑌(𝐸)𝐸𝐴𝐹(𝑇←𝑆,𝐸𝑖 ,𝑡)𝑑𝐸
𝑀𝑇 (𝑡)

(2)

Where, wr,I is the radiation weighting factor applicable to the i-th radiation, Yi is the intensity of the
radiation, Ei is the energy of the i-th discrete radiation emitted by the radionuclide per nuclear
transformation, MT(t) is the mass of the target tissue T at age t, 𝑨𝑭(𝑻 ← 𝑺, 𝑬𝒊 , 𝒕) is the absorbed
fraction quantity representing the fraction of the energy emitted in S that is absorbed in T for an
individual of age t and Y(E) dE denotes the number of electrons in the beta or positron spectrum with
energy between E and E + dE [1].

Each biokinetic model consists of multiple compartments corresponding to an individual organ. The
translocation from consecutive compartments is governed by first order kinetics. The solution gives the
time dependent distribution of the radionuclide and its daughter, if applicable. If Ai,j(t) is the activity of
the radionuclide i in compartment j at time, the number of nuclear transformations in a compartment is
governed by the following first order differential equation [1].

𝑑𝐴𝑖,𝑗 (𝑡)
𝑑𝑡

𝑝

𝑝

𝑀
𝑖−1
= ∑𝑀
𝑘=1 𝐴𝑖,𝑗 𝜆𝑖,𝑘,𝑗 − 𝐴𝑖,𝑗 [ ∑𝑘=1 𝜆𝑖,𝑘,𝑗 + 𝜆𝑖 ] ∑𝑘=1 𝐴𝑘,𝑗 𝛽𝑘,𝑖 𝜆𝑖
𝑗≠𝑘

𝑗≠𝑘

Where:
M is the number of compartments describing the kinetics
𝝀𝒊,𝒌,𝒋 is the fractional transfer rate, of chain member i from compartment j (donor
compartment) to compartment k (receiving compartment).
𝒑

𝝀𝒊 is the decay constant of chain member i and
4

(3)

𝜷𝒌,𝒊 is the fraction of decays of chain member k forming member i.
For example, using equation 3, the first compartment of the ICRP 30 gastrointestinal tract model, the
stomach, the first order differential equation is given by equation 4 [1].

𝑑
𝑞
𝑑𝑡 𝑆𝑇

= −𝜆𝑆𝑇 𝑞𝑆𝑇 (𝑡) − 𝜆𝑅 𝑞𝑆𝑇 (𝑡) + 𝐼(𝑡)

(4)

Where
I(t) is the rate of ingestion of a radionuclide
λST is the transfer coefficient of the stomach
λR is the decay constant of the radionuclide
2.3 Annual Limit on Intake

The current occupational exposure for ionizing radiation limit by the NRC is expressed as a total effective
dose equivalent equal to 0.05 Sv or the committed equivalent dose to any organ other than the eye
being equal to 0.5 Sv [6]. ICRP 60 updated recommendation to an intake of a radionuclide that would
lead to a total effective dose of 0.02 Sv per year averaged over five years with the addition that the
effective dose does not exceed 50 mSv in a year [2]. In the event skin contamination occurs,
10CFR20.1201 limits shallow dose to the skin to 0.5 Sv to the skin of the whole body or to the skin of an
extremity. The shallow dose must be averaged over the 10 cm2 receiving the highest exposure [6]. The
annual dose limit applies to the sum of the effective doses from external radiation and the committed
effective dose from intakes of radionuclides occurring within the one-year period [1]. In occupational
exposure, doses are commonly received from external and internal sources. For external exposures,
individually monitoring is typically performed by measuring individual dose equivalents using personal
dosimeters. On the other hand, for internal exposures, committed effective dose values are determined
from bioassay samples or in the workplace. Internal exposure can also be described through the use of
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dosimetric models for long periods of time. Calculated ALI are based solely on radiation dose and does
not take into account the chemical effects [1].

2.4 Skin Dose Calculation
The NRC utilizes VARSKIN code, a tool used to assess doses from skin contamination. Varskin performs a
five-dimensional integration of the source volume and the target area [7]. The mathematical kernel used
calculate the dose by the code is

𝐵(𝑟) =

𝑟
𝑘𝐸𝛽 𝑌𝐹𝛽 ( 1 )
𝑋99

𝜋𝜌𝑟 2 𝑋99

(5)

Where:
r is the distance between the source point and the dose point
k is a unit conversion constant
Eβ is the average beta energy
Y is the beta yield per disintegration
Fβ(r1/X99) is the scaled absorbed dose distribution
r1 is the modified path length between a source point and the dose point
ρ is the density of the material

2.5 ICRP Publication 30 Dosimetric Model for the Gastrointestinal Tract
The dosimetric model for the gastrointestinal tract provides an important tool for the determination of
internal dose to a worker after ingestion of a radionuclide [1]. The model employs the same general
method used to calculate H50,T. The methods used to calculate the number of transformations in the
source organ, US, and H50 are discussed. The gastrointestinal model breaks the system into separate
sections and these sections are treated as separate target tissues. ICRP 30 breaks the colon into the
6

upper large intestine (ULI) and the lower large intestine (LLI). The ULI refers to the ascending and
transverse colon and the LLI includes the descending, sigmoid colon, and rectrum. Figure 1 displays the
different components that make up the GI tract dosimetric model from ingestion to excretion [1]

Figure 1: ICRP 30 Gastrointestinal Tract Model
Table 2: ICRP 30 transfer rates for each compartment of the GI tract model

The value λB, corresponds to the transfer rate of material to the body fluids and can be estimated from
f1, the fraction of a stable element that reaches the body fluids following ingestion [1].
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𝜆𝐵 =

𝑓1 𝜆𝑆𝐼
1−𝑓1

(6)

The values of f1 are provided by metabolic data for various classes of compounds of individual isotopes.
In addition, in the case of radioactive daughter isotopes the value of f1 is taken to be the stable isotope
from which the ingested radionuclide is an isotope [1].

𝑓1 = 𝜆

𝜆𝐵
𝑆𝐼 +𝜆𝐵

(7)

In addition, absorption of ingested radioactivity is assumed to occur in the small intestine and can be
described by element specific “f1” values [1]. The f1 values represent fractional absorption of the stable
element to the blood.

Absorbed fractions estimations for beta and alpha particles due to the contents in the GI tract are
assumed to be 1 and 0.01, respectively [1]. This is in addition to the dose to the walls of the GI tract
from absorbed activity, particularly long-lived radionuclides. This is usually the dominant source of dose
to the walls in the GI tract.

2.6 ICRP 100 Human Alimentary Tract Model
In 2006, the ICRP updated the ICRP 30 gastrointestinal tract model in ICRP publication 100. In 2015, the
ICRP published ICRP publication 130 adopting the ICRP 100 HATM, formally replacing ICRP Publication 30
gastrointestinal tract model [8]. This replacement of the ICRP 30 model was motivated by a number of
developments including improved information on the gut transit of materials and the increased
awareness of the location of sensitive cells [9]. The most important feature of the HATM is the
calculation of doses to target regions containing sensitive cells for cancer induction [9]. The ICRP 100
HATM also allows for retention in alimentary tract walls and absorption to the blood from other areas
within the GI tract. One prominent difference between the ICRP30 model and the HATM is that the
8

HATM assumes a longer transit time through the alimentary tract and therefore a slower rate of fecal
excretion for the first few days after ingestion of a radionuclide.

Unlike the dosimetric model for the GI tract, the HATM also accounts for entrance into the esophagus
after particle transport from the respiratory tract [9]. It describes the sequential transfer through all
alimentary tract regions including the oral cavity, esophagus, stomach, the small intestine, and colon,
followed by the excretion of feces. The doses are calculated for each region. Based on the availability of
transit time data, the colon is separated into right colon, left colon, rectosigmoid (the sigmoid colon and
rectum) [9]. The sigmoid colon and the rectum are considered together because the transit times for
each separately have not been determined and there is no specific WT value for the rectum. The HATM
and the ICRP 30 model yield similar tissue dose estimates for most radionuclides. However, in some
cases the HATM will yield substantially different doses to walls of the alimentary tract due to the
specification of retention of radionuclides in the walls of the tract and the explicit modeling of the
sensitive cells of different regions of the GI tract in the HATM model [9]. The HATM is compatible with
and inter-connected to the Human Respiratory Tract Model (HRTM) published in ICRP 66. Figure 2
displays the HATM model [9].

The updated HATM is much more complex than the ICRP 30 GI tract model. The HATM depicts the entry
of a radionuclide into the oral cavity through ingestion or into the esophagus following mechanical
clearance from the respiratory tract. In addition, the model also incorporates radionuclide deposition
and retention on or between the teeth and return to the oral cavity and in the walls of the stomach and
intestine, transfer from the walls of the stomach and the intestines back into luminal contents or the
blood [9]. This process is referred to as absorption.
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Figure 2: ICRP 100 Human Alimentary Tract Model

The dashed boxes represent connection to organs with the respiratory tract model or systemic
biokinetic model and are therefore, not part of the HATM model [9]. In addition, the HATM model
assumes first order kinetics, which provides simplification of the process but provides an accurate
representation of the mean residence time of a radionuclide in each element of the tract. Each
parameter in the model is represented by a transfer coefficient, which describes the outflow rate of a
material from a compartment. The transfer coefficient is described as the instantaneous fraction of the
contained material leaving the compartment per unit time. Parameters used in the model may be
generic values or element specific values. Generic values refer to values that describe bulk flow of
material through the lumen of the alimentary tract [9]. These values are given in the form of age,
gender, and material specific transit times. The element specific values are those that describe
retention in or on the tissue, absorption to blood, and secretion from systemic organs or blood into the
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lumen of the tract. Minimal element specific parameters are available and where not available, the
coefficient is assumed to be zero [9].

2.6.1. Transit Times
Transit through the lumen of the tract depends on the compartment of concern. The transfer of
material from the oral cavity to the esophagus is represented by a single transit time that is dependent
on the type of material entering the oral cavity [9]. Default times are available for liquids, solids, and
total diet.

The transfer of material from the esophagus to the stomach is described by two transfer rates. Most
swallowed food reaches the stomach in a matter of a few seconds. However, there is evidence from
studies of labeled material fed by mouth that a portion of swallowed food may take longer for
clearance, usually within a few minutes but sometimes longer [9]. This longer retention time may also
be present in the case of inhaled material transferred to the alimentary tract by mechanical transport.
Each of the two components of transfer from the esophagus to the stomach is represented by a single
transit time, which is dependent on the type of material

Transfer from the stomach to the small intestine is represented by a single transit time that depends on
the type of material entering the stomach. Default transit times are provided for water or other noncaloric liquids, caloric liquids, solids, and total diet. After the small intestine, the transit time is assumed
to be independent of the type of material that initially entered the alimentary tract [9]. In addition,
transfer from the small intestine to the right colon as well as each following sequential transfer is
represented by a single transit time.
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Table 3: Transfer Coefficients from ICRP 100 for the HATM

2.6.2 Absorbed Fraction
ICRP 100 also updated the way absorbed fractions were determined for alpha particles and electrons.
For electrons, it was determined that the approach taken in ICRP 30 may lead to a substantial
overestimation. In most cases, the absorbed fraction for alpha particles will be zero based on the
location of the sensitive cells. This is true for all isotopes of uranium. Absorbed fractions for electrons
are based on geometric models and were calculated using MCNP General Purpose Monte Carlo Code.
The absorbed fractions for electrons in each region of the alimentary tract can be found in Table F.1 in
Annex F of ICRP 100 [9].

2.6.3 Absorption, Retention, and Secretion of Radionuclides

The dose delivered to regions of the alimentary tract depends on two main things, the rate of transfer
through the lumen and the extent of the radionuclide’s absorption to the blood and distribution in other
tissues. Certain regions of the alimentary tract account for a great amount of absorption with the main
region being the small intestine [9]. Absorption refers to the process that leads to the transfer of
radionuclides from the alimentary tract to the blood and then to other tissues in the body. With high
levels of absorption in the small intestines, smaller doses are usually present in the large intestine. Since
the alimentary tract is a route of excretion variable portions of certain radionuclides may pass through
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the large intestine. Doses to regions of the alimentary tract may also arise from radionuclides carried in
the blood or deposited in tissues after absorption. Absorption depends on the chemical properties of
the radionuclide as well as the specific form of the intake [9]. For example, cesium behaves similar to
potassium and therefore will be rapidly absorbed. Additional dose may result with retention of
radionuclides on the tissues of the alimentary tract. This is of particular concern because there is
evidence of retention in the small intestine.

In general, the absorption of radionuclides occurs with nutrient absorption in the small intestine.
Absorption may occur through two different processes. The first involves passive diffusion while the
second is active transport through the single layer of epithelial cells lining the small intestine.
Although a majority of absorption occurs within the small intestine there is evidence to suggest that
absorption of some elements and their radioisotopes may occur in other regions of the alimentary tract.
The other regions include the mouth, stomach, and colon [9]. The large intestine is known to absorb
water and electrolytes such as sodium and chloride while the stomach absorbs highly lipid soluble
substances. In addition, there is some evidence to suggest the absorption of some elements including
iodine, copper, and mercury in the stomach.

2.6.4 Details of the Colon
The fraction of the alimentary tract extending from the caecum to the anus contains three regions: right
colon, left colon, and rectosigmoid. The right colon is defined as the caecum, ascending colon, and
proximal half of the transverse colon. The left colon is the distal half of the transverse colon plus the
descending colon . Finally, the rectosigmoid includes the sigmoid colon and the rectum [9]. This division
of the colon differs from the previous model of the gastrointestinal tract but is a standard division for
diagnostic and experimental examinations of colonic transit. In addition, considerable information is
available on transit times through each of these three sections. From ICRP Publication 100, the Task
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Group concluded that the division of the large intestine into these segments allows for the best estimate
of the time-dependent distribution of ingestion, inhalation, or secreted activity in the colon [9].

Although the rectum serves mainly as a channel for conveying, it may also serve as a storage organ
when the amount of material is too small to induce defecation or is not convenient leading to a large
amount of material being stored. Therefore since the transit time for material in the rectum is difficult,
the rectum is not considered as a separate compartment [9].

2.7 ICRP 30 Metabolic Data for Uranium

Figure 3: Metabolic model for uranium

Figure 3 outlines the uranium metabolic model from ICRP 30 [10]. Based on numerous studies
investigating the uptake of uranium to the blood, anywhere from 0.005 and 0.05 of the compound is
absorbed. ICRP 30 assumes an f1 value of 0.002 for relatively insoluble compounds of uranium such as
UF4, UO2, and U3O8 and water-soluble inorganic compounds of uranium, the f1 is taken to be 0.05 [10].

14

The retention and distribution of uranium in bone and kidney have been determined using post-mortem
data as well as intake from normal dietary uranium. It is assumed fractions 0.2 and 0.023 go to mineral
bone and are retained with a half-life of 20 and 5000 days. In addition, fractions 0.12 and 0.00052 are
assumed to go to the kidneys with half-lives of 6 and 1500 days, respectively. Finally, fractions 0.12 and
0.00052 are assumed to go to all other tissues and are retained for 6 and 1500 days [10]. The remaining
fraction of uranium entering the transfer compartment is assumed to go directly to excretion.

2.8 ICRP 69 Uranium Systemic Model
Due to updated available information on actinides, the ICRP 30 metabolic data for was updated in 1995
in ICRP publication 60 to include additional compartments [11]. This general model for actinides was
adapted for uranium in ICRP 69. The model is based on an age-specific biokinetic model for calcium like
elements proposed by Leggett [12]. One difference between the proposed model by Leggett and the
updated ICRP model is the inclusion of two liver compartments in the ICRP model for actinides [11].

The model includes entrance of uranium into the blood compartment through the gastrointestinal tract
as well as the respiratory tract. The blood is treated as a uniform mixed pool. The uranium model also
includes a red blood cell compartment, which exchanges with the plasma. As mentioned, the liver is
separated into two compartments, Liver 1 and Liver 2. Liver 1 is considered the transit compartment and
has a short retention time. Liver 2 is considered the storage compartment and has a long retention time
(T1/2> 1 year). Soft tissues, excluding liver and kidneys, are divided into three different compartments,
slow, intermediate, and fast return of activity to the plasma. These compartments are labeled ST2, ST1,
and ST0 in the ICRP 69 biokinetic model. ST0 includes extracellular fluids and transfers material over
hours or days. This compartment serves two purposes, to represent early build up and decline of
material as well as to account for early feedback into the blood. On the other hand, compartment ST1
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represents intermediate retention, up to 2 years and ST2 represents long-term retention, for many
years. Both compartments represent “massive soft tissue” including muscle, skin, and subcutaneous fat.
The bone is broken down into cortical surface, cortical volume, exchange and non-exchange, trabecular
surface, and trabecular volume, exchange and non-exchange. Activity transferring from the bone
surface to the bone volume, is assumed to enter the exchange compartment where it is removed to
either the non-exchange volume or to the blood system with an element specific half-time. From the
non-exchange volume, material is assumed to be removed to plasma by bone resorption [11]. For
dosimetry purposes it is assumed that activity is evenly distributed in the bone volume, exchange and
non-exchange. In addition, bone marrow is considered as part of other soft tissues. In the case of
excretion, activity is assumed to go directly to urine from the plasma and the gastrointestinal tract for
feces. The additional compartment in the kidneys represents the retention in the renal tubes before
excretion. Figure 4 displays the uranium systemic model from ICRP 69 [11].
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Figure 4: ICRP 69 systemic system biokinetic model for uranium
Table 4 displays the transfer coefficients for the ICRP 69 uranium systemic model.
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Table 4: ICRP 69 transfer coefficients for the uranium systemic model
ICRP 69 Uranium Systemic System Transfer Coefficients
Transfer Coefficient (s-1)

Path
From Plasma to:
ST0
RBC
Urinary bladder contents
Kidney 1
Kidney 2
Upper large intestines content
Liver 1
ST1
ST2
Trabecular bone surface
Cortical bone surfaces

0.000121528
2.83565E-06
0.000178588
3.40278E-05
1.41204E-07
1.41204E-06
4.24769E-06
1.88657E-05
8.50694E-07
2.36111E-05
1.88657E-05

To Plasma From:
ST0
RBC
Kidney 2
Liver 1
Liver 2
ST1
ST2
Bone surfaces
Nonexch trabecular Bone Volume
Nonexch cortical Bone Volume

9.62963E-05
4.0162E-06
4.39815E-09
1.06481E-06
2.19907E-09
4.0162E-07
2.19907E-10
8.02083E-07
5.70602E-09
9.50231E-10

Kidney 1 to urinary bladder contents
Liver 1 to liver 2
Bone surfaces to exchangeable bone volume
Exchangeable bone volume to bone surfaces
Exchangeable bone volume to
nonexchangeable volume

1.14583E-06
8.02083E-08
8.02083E-07
2.00231E-07
6.68981E-08

2.9 Gastrointestinal Procedures
There is an increasing number of patients who undergo surgery on their GI tract for various reason
including cancer, Crohns disease, as well as other medical conditions. These surgeries result in a change
in pathway for an ingested radionuclide. According to United Ostomy Association of America, 750,000
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are living with an ostomy and over 130,000 new life-saving ostomies occur in America every year [13].
An ostomy refers to a surgically created opening in the body for the discharge of wastes. When
temporarily implemented, this allows time for the organ to heal. On the other hand, some ostomies may
be permanent. There are two main types of ostomies performed each year that affect the GI tract,
including colostomy and Ileostomy.

2.9.1 Colostomy
A colostomy requires bringing one end of the large intestine out through an opening made in the
abdominal wall [13]. The large intestine is connected to the small intestine and consists of the two main
sections, the colon and the rectum. The small intestine is the primary area of nutrient digestion,
including fats, protein, and carbohydrates, which are then absorbed into the blood vessels. The food
that cannot be absorbed moves from the small intestine to the large intestine, or more specifically, the
colon, where mainly water is absorbed from the waste. The waste is continuously stored in the colon
until the next bowel movement where it will eventually make its way down to the rectum.

As indicated in Figure 5, there are various colostomy types [14]. There are three main types of
colostomies. The ascending colostomy is performed in the ascending colon and allows a majority of the
colon to rest. A traverse colostomy, which affects the upper large intestine in the transverse colon, like
the ascending colostomy allows for the colon to rest but allows a shorter segment of the colon to
recover. The descending and sigmoid colostomies, which affect the lower large intestine and mainly
allows for the rectum to heal [13].
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Figure 5: Location in the large intestine for each type of colostomy
The type of approach the surgeon takes depends on the other types of procedures that need to be
performed. In general, the incision is made in the middle of the abdomen and the bowel resection and
repair is done as needed. An incision is made in the abdomen wall. Once the incision is made, one end
of the healthy colon is brought through the opening, normally on the left side. The surgically created
opening of the large intestine is referred to as the stoma [13]. The edge of the bowl are stitched to the
skin of the opening creating a stoma. On the outside of the opening a bag is placed called a stoma
appliance. The bags allows for the collection of stool. The pouching systems may include a one or twopiece system. The one piece system consists of a plastic bag for collection. The two-piece system
includes a mounting plate and the collection pouch. The bag attaches to the skin barrier and is fit over
the stoma [13]. The colostomy bag is attached with an adhesive. The bags are designed to be air and
watertight but may become dislodged or loose overtime due to loss of adhesion. Figure 6 displays an
example of a colostomy bag [15].
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Figure 6: Colostomy collection bag
If a person requires surgery on a portion of their large intestine, a colostomy provides short-term rest
and allows for recovery [13]. Once the large intestine has recovered from surgery, the patient will have
to undergo another surgery to reattach the ends of the large intestine. There are numerous reasons a
person may have to undergo a colostomy. These range from infection of the abdomen, injury to the
colon or rectum, blockage of the large bowel, rectal or colon cancer, or wounds in the perineum [13].

2.9.2 Descending and Sigmoid Colostomies
A descending colostomy is located in the descending portion of the colon. This portion of the colon takes
the waste down the left hand side of the abdomen as shown in Figure 5 [13]. In a similar fashion, a
sigmoid colostomy is located in the bottom portion of the large intestine.

2.2.3 Transverse Colostomy
A transverse colostomy is located in the transverse colon, as seen in Figure 5 [13]. The transverse colon
crosses the top of the abdomen. There are two types of transverse colostomies, the loop colostomy
where the entire loop of bowel brought to the skin surface and the end is opened to create a non-
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functioning end. The second is a double barrel colostomy where the colon is divided into two stomas
[13].
2.2.4 Ascending Colostomy
As indicated in Figure 5, an ascending colostomy is located in the ascending colon [13]. This is an
extension of the beginning of the large intestine to the right side of the abdomen. This procedure
results in only partial function of the colon. This type of procedure is rare and an Ileostomy is usually
more appropriate [13].

2.3 Ileostomy
The ileum is the lowest portion of the small intestine. Therefore, an Ileostomy refers to the a procedure
in which the surgeon creates an opening in the stomach wall and brings the end of the ileum through
the opening and attaches it the skin to create the stoma [9]. Figure 7 shows the placement of an
Ileostomy in the small intestine [13].

Figure 7: Location of Ileostomy
From the image, it is evident that through an Ileostomy, both the colon and the rectum are removed
from the pathway for exiting waste. Like the other colostomies, ileostomies can be permanent or
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temporary and varies between patients depending on the severity of the medical issue [13]. If an
Ileostomy is temporary, this most likely means part of the colon has been removed but part of the
rectum remains. This could result from surgery performed on part of the large intestine. The surgeon
would perform an Ileostomy, allowing the large intestine to rest. When the Ileostomy is no longer
required, another surgery is required to reattach the small intestine. An Ileostomy is required long term
if both the large intestine and rectum have been removed [13]. There are numerous reasons a person
would require an Ileostomy including, inflammatory bowel disease, colon or rectal cancer, familial
polyposis , birth defects, or an accident involving damage to the intestines [13]. The pouching system
for an ileostomy is the same appliance used for a colostomy and is attached through adhesion.
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3.0 Model Development
3.1 MATLAB Simulink
For this research, MATLAB Simulink is utilized to model each dosimetric system. MATLAB is a software
for scientists and engineers to analyze data, develop algorithms, and create models [16]. The Simulink
suite was included in the MATLAB student version 8.6.0.267246 (R2015b). Simulink is a block diagram
setting that allows for modeling and simulating dynamic systems [16]. Simulink provides a graphical
interface, predefined blocks as well as user defined blocks that can be combined to create a unique
system. One of Simulink’s key features is the simulation engine with fixed step and variable-step ODE
solvers. The solvers are numerical integration algorithms that compute the system dynamics over time
using the information contained within the model [16]. The fixed step solver computes the time of the
next simulation step by adding a fixed step to the current time. A variable-step solver varies the step
size based on the local error to achieve the specified tolerance [16]. With the availability of fixed step
and variable-step solvers in Simulink and the customizable block diagram setting a series of ordinary
differential equations can be solved sequentially.

3.2 MATLAB Simulink Modeling
With the use of Simulink, the determination of the distribution and exchange of a radionuclide and its
daughters through the human body using a series of ordinary differential equations is possible. The
setup of each compartment in the model was based on previous research performed by Hrychushko
[17].With the use of Simulink modeling, the initial intake and model pathways can be easily altered to
allow for varying simulations and dose determinations.

For example, when looking at the transfer of material in the stomach compartment to the ULI from the
ICRP 30 gastrointestinal tract model, shown in Figure 8.
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Figure 8: Stomach compartment from
ICRP 30 GI tract model

The resulting differential equation, using Equation 3, for the activity as a function of time within the
stomach is given by equation 8 [1].

𝑑
𝑞
𝑑𝑡 𝑆𝑇

= −𝜆𝑆𝑇 𝑞𝑆𝑇 (𝑡) − 𝜆𝑅 𝑞𝑆𝑇 (𝑡) + 𝐼(𝑡)

(8)

Where:
λST is the transfer coefficient of the stomach
λR is the radioactive decay constant of the radionuclide
qST(t) is the activity of the radionuclide ingested at time t in the stomach
I(t) is the rate of ingestion of activity of the radionuclide
The integration over 50 years, solved using MATLAB Simulink’s variable step ODE solver, gives the total
number of transformations in the stomach. Figure 9 displays the blocks used to determine the number
of transformations in 50 years in the stomach compartment from the ICRP 30 GI tract model based on
Equation 9.
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Figure 9: Detail showing the blocks used to calculate transformations
in 50 years in the stomach compartment
The calculation of the contribution to dose from the presence of the daughter isotopes, where
applicable, was included in the dose calculation since it improved the accuracy of the total dose to the
ICRP reported values. For example, the activity of the daughter radionuclide in the stomach
compartment is determined by Equation 9 [1].

𝑑 ′
𝑞 (𝑡)
𝑑𝑡

′ (𝑡)
′ (𝑡)
= −𝜆𝑆𝑇 𝑞𝑆𝑇
− 𝜆′𝑅 𝑞𝑆𝑇
+ 𝜆′𝑅 𝑞𝑆𝑇 (𝑡)

(9)

Where
λ’R is the decay constant of the daughter radionuclide
q’ST (t) is the activity of the daughter in the stomach and q(t) is the activity of the immediate
parent

Figure 10 displays the blocks used to calculate the number of transformations for the first daughter in
the stomach compartment based on Equation 9.
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Figure 10: Blocks used to calculated the number of transformations for the parent and
first daughter in the stomach compartment

Each compartment also included the calculation to determine the SEE. This calculation is based on
Equation 2 and is given by Equation 10 [1].

𝑆𝐸𝐸(𝑆𝑇 ← 𝑆𝑇) =

𝑌𝑖 𝐸𝑖 𝐴𝐹(𝑆𝑇←𝑆𝑇)𝑖 𝑄𝑖
𝑀𝑇

Where
Yi is the yield of radiations of time i per transformation
Ei is the energy of radiation I
AF is the absorbed fraction in the stomach from radiation i
MT is the mass of the target organ
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(10)

Qi is the quality factor of the radiation; Q is 20 for alpha particles and 1 for electrons

For alpha particles and electrons the specific absorbed fraction (SAF) is given by equation 11 [1].
1

𝑆𝐴𝐹 = 2𝑀 𝜈
𝑇

(11)

Where 𝒗 represents the degree to which the radiation penetrates the mucus and ranges between 0 and
1. The value of 𝒗 for electrons and alpha particles is 1 and 0.01, respectively [1]. The absorbed fraction
is determined by the energy of the radiation for photons. Therefore, in order to determine the absorbed
fraction for photons, a user defined Simulink function block was used to interpolate the values given in
ICRP 23 with the target being the stomach wall and the source being the stomach contents. The organ
dose was then determined by Equation 1. Figure 11 displays the blocks used to determine the number
of transformations, SEE value, and organ dose for the stomach compartment.

Figure 11: Details including the various blocks used in the stomach subsystem
Figure 11 only displays the detail of the stomach but the same approach was applied to each organ in
the biokinetic model. In order to simplify the display of each model each organ was represented by
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creating a subsystem. A subsystem displays only the basic information including any blocks used for
inputs into inports such as constants or functions. It also displays outputs from the exports, represented
by sinks. Sinks may include graphs or numerical displays. In the model, a subsystem represents a specific
organ or tissue. This keeps blocks functionally related to one another together. Each subsystem can be
connected through inports and exports to represent the exchange of a radionuclide from one
compartment to the next.

Figure 12 displays an example of a subsystem, the stomach compartment of the gastrointestinal tract
model from ICRP 30.

Figure 12: Single subsystem, the stomach, from the ICRP 30 GI tract model
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From the subsystem, the inports include the ingestion, uranium half-life, thorium half-life, protactinium
half life, and the initial activity in the stomach. The values were input based on the properties of the
uranium isotope of interest and its daughters. For example, constants were used for the half-lives and
initial activity as inputs into the inports. On the other side, the exports include the transfer of material to
the small intestine, the transformations for each radionuclide, Us, occurring in the stomach, and the
organ dose. Exports can be used to output values, using sinks, or connect subsystems. For example, the
export for transfer of material to the small intestine was connected to the inport on small intestine
subsystem and the number of transformations were output using a display block.

Figure 13: The four subsystems of the ICRP 30 GI tract model and how each inport and export connects
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Figure 13 displays the four subsystems (stomach, SI, ULI, LLI) comprising the ICRP 30 GI tract model and
how the inport and export of each subsystem can be connected to couple the differential equations
described by each subsystem.

3.3 Development of Baseline Model
In order to perform analysis to determine the effects a gastrointestinal procedure may have on internal
dosimetry, ICRP 30 gastrointestinal tract model, ICRP 30 metabolic data for uranium, ICRP 100 Human
Alimentary Tract Model (HATM), and ICRP 69 uranium systemic model were modeled using Simulink in
the same manner as described in Figures 9-13. The ICRP 30 GI tract model was connected to the ICRP 30
metabolic model for uranium and the ICRP 100 HATM and ICRP 69 uranium systemic model were
connected. The ICRP 30 GI tract model was used because it is currently used by the NRC for federal
regulation. On the other hand, ICRP 100 HATM model and ICRP 69 uranium systemic model was used
because they are the most up to date models of the GI tract and blood system due to the updated
available information since the ICRP 30 model.

Each model was used to determine the number of transformations, the SEE values, and organ equivalent
dose. Using the organ equivalent doses and the tissue weighting factors from Table 1, the total body
effective dose was determined for ingestion and injection pathways for each uranium isotope. The
effective dose was determined using ICRP 26 tissue weighting factors for the ICRP 30 GI tract and ICRP
30 uranium systemic model combination. The whole body effective dose was determined using two
methods for the ICRP 100 HATM and ICRP 69 systemic system model combination. The tissue weighting
factors from ICRP 60 and ICRP 103 were applied and compared.
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An instantaneous ingestion of 1 Bq was modeled for each combination. Specific model configuration
parameters values were input into the system and were held constant. This allowed for reproducibility.
For example, the half-life for 238U is 4.47x109 years and the initial activity in each organ was assumed to
be zero. A variable-step type solver was utilized in each model. The use of a variable-step type solver
reduces the step size when the state of the model changes rapidly to increase the accuracy [16]. It was
determined running a fixed step size had no effect on the final dose calculation and resulted in
significantly longer run times. Therefore, the step size was set to auto. In addition, the default
differential equation solver, ode45, was used in each model. Ode45 is a MATLAB solver that uses a
Runge-Kutta method for solving ordinary differential equations [16]. Finally, the relative and absolute
tolerances were set to default as changing the tolerance to low values did not change the accuracy of
the results. Simulink automatically sets the relative tolerance and absolute tolerance to 10-3 and 10-6,
respectively [16].

3.4 Benchmarking the Baseline Model
In order to validate each model was running as expected the values output from the model were
compared to the ICRP 30 literature values [1]. The ICRP 30 GI tract model was connected with the model
for ICRP 30 metabolic data for uranium. To achieve this, an instantaneous ingestion of 1 Bq was
assumed to occur at time t=0 and was represented by a step function in the Simulink model. Table 5
displays a comparison between the SEE values output by the Simulink model and the ICRP 30 literature
values for 238U and its daughters, 234Th and 234mPa [1].
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Table 5: SEE values determined by the Simulink model and literature values from ICRP 30
Specific Effective Energy (MeV per g per transformation) of U-238
Target Organ

ULI
LLI
Cortical Bone
Trabecular
Bone
Kidney

U-238
Simulink
Model
1.9E-03
3.1E-03
7.0E-03

ICRP 30
1.9E-03
3.1E-03
7.0E-03

Th-234
%
Simulink
Error Model
0
1.3E-04
0
2.1E-04
0
7.7E-06

Pa-234m

1.4E-04
2.2E-04
7.8E-06

%
Simulink
Error Model
7.14 1.7E-03
4.55 2.8E-03
1.28 9.8E-05

ICRP 30

1.9E-03
3.0E-03
1.0E-04

%
Error
10.53
6.67
2.00

ICRP 30

1.7E-02

1.7E-02

0

1.2E-05

1.3E-05

7.69

1.6E-04

1.7E-04

5.88

2.7E-01

2.8E-01

3.57

1.9E-04

2.0E-04

5.00

2.4E-03

2.7E-03

11.11

Similarly, the number of nuclear transformations over 50 years per unit intake of 238U resulting from the
Simulink model were compared to the ICRP literature values. The values for 238U, 234Th and 234mPa are
displayed in Table 6 [1].
Table 6: Number of nuclear transformations, Us, determined by the Simulink model and literature
values from ICRP 30
Number of Transformations Over 50 Years per Unit of Intake (Transformations/Bq) U-238
Target Organ

ULI
LLI
Cortical Bone
Trabecular
Bone
Kidney

U-238
Simulink
Model
47900
86230
21888

Th-234

Pa-234m

47000
86000
22000

%
Simulink
Error Model
1.91
1034
0.27
4220
0.51
14880

5472

5500

0.51

3720

5300

29.8

374

370

1.08

167

230

27.4

ICRP 30

990
4200
21000

%
Error
4.4
0.5
29.1

Simulink
Model
1033
4218
10312

ICRP 30

990
4200
21000

%
Error
4.3
0.4
50.9

2578

5300

51.4

115

230

50.0

ICRP 30

Finally, the committed dose equivalent values and weighted dose equivalent output from the ICRP 30 GI
tract Simulink model were compared to the literature values in ICRP 30 for 238U. The values are displayed
in Table 7 and Table 8, respectively [1].
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Table 7: Committed dose equivalent for target organs resulting from the Simulink model and
literature values from ICRP 30 for U-238
Committed Dose Equivalent per Unit of Intake (Sv/Bq) U-238
Target Organ
Simulink Model
ICRP 30
% Error
ULI
1.49x10-8
1.50x10-8
0.67
-8
-8
LLI
4.483x10
4.60x10
2.54
Bone Surface
3.993x10-8
4.0x10-8
0.25
Kidney
1.621x10-8
1.70x10-8
4.65
Table 8: Effective Dose for target organs calculated by the Simulink model compared to the literature
ICRP 30 values for U-238
Effective Dose per Unit of Intake (Sv/Bq) U-238
Target Organ
Simulink Model
ICRP 30
% Error
ULI
8.94x10-10
8.7x10-10
2.76
-9
-9
LLI
2.69x10
2.7x10
0.37
Bone Surface
1.2x10-9
1.2x10-9
0
Kidney
9.73x10-10
1.0-9
2.7
The same benchmark procedure was performed for 233U, 234U, and 235U for the ICRP 30 model. Tables 914 display the committed dose equivalent and the effective dose for each target organ from the
Simulink model as well as the literature values from ICRP 30 and the calculated percent error.
Table 9: Committed Dose Equivalent for target organs calculated by the Simulink model compared to
the literature ICRP 30 values for U-234
Committed Dose Equivalent per Unit Intake (Sv/Bq) U-234
Target organ
ULI
LLI
Bone Surface
Kidney

Simulink Model
1.66E-08
4.85E-08
4.51E-08
1.83E-08

ICRP 30
1.60E-08
4.90E-08
4.50E-08
1.90E-08

% Error
3.44
0.94
0.2
3.53

Table 10: Effective Dose for target organs calculated by the Simulink model compared to the literature
ICRP 30 values for U-234
Effective Dose per Unit Intake (Sv/Bq) U-234
Target organ
ULI
LLI
Bone Surface
Kidney

Simulink Model
9.93E-10
2.91E-09
1.35E-09
1.10E-09

ICRP 30
9.7E-10
3.0E-09
1.4E-09
1.1E-09

% Error
2.37
3.00
3.57
0.00

Table 11: Committed Dose Equivalent for target organs calculated by the Simulink model compared
to the literature ICRP 30 values for U-233
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Committed Dose Equivalent per Unit Intake (Sv/Bq) U-233
Target organ
ULI
LLI
Bone Surface
Kidney

Simulink Model
1.67E-08
4.88E-08
4.54E-08
1.85E-08

ICRP 30
1.60E-08
5.00E-08
4.60E-08
1.90E-08

% Error
4.06
2.32
1.26
2.89

Table 12:Effective Dose for target organs calculated by the Simulink model compared to the
literature ICRP 30 values for U-233
Effective Dose per Unit Intake (Sv/Bq) U-233
Target organ
ULI
LLI
Bone Surface
Kidney

Simulink Model
9.99E-10
2.93E-09
1.36E-09
1.11E-09

ICRP 30
9.8E-10
3.0E-09
1.4E-09
1.1E-09

% Error
1.94
2.33
2.86
0.91

Table 13: Committed Dose Equivalent for target organs calculated by the Simulink model compared to
the literature ICRP 30 values for U-235
Committed Dose Equivalent per Unit Intake (Sv/Bq) U-235
Target organ
ULI
LLI
Bone Surface
Kidney

Simulink Model
1.72E-08
5.26E-08
4.15E-08
1.74E-08

ICRP 30
1.70E-08
5.20E-08
4.20E-08
1.70E-08

% Error
1.12
1.10
1.26
2.24

Table 14: Effective Dose for target organs calculated by the Simulink model compared to the
literature ICRP 30 values for U-235

Effective Dose per Unit Intake (Sv/Bq) U-235
Target organ
ULI
LLI
Bone Surface
Kidney

Simulink Model
1.03E-09
3.15E-09
1.24E-09
1.04E-09

ICRP 30
1.00E-09
3.20E-09
1.3E-09
1.00E-09
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% Error
3.00
1.56
4.62
4.00

The ICRP 100 model could not be benchmarked for the alimentary tract because the ICRP has not
released updated dose coefficients for uranium using the new model. However, ICRP 130 plans to
update the uranium dose coefficients in a future publication, which are necessary for benchmarking the
model. However, the systemic system, ICRP 69 used in conjunction with ICRP 100 HATM was
benchmarked using the dose coefficients provided in ICRP 69 for 238U. ICRP 69 uses an f1 value of 0.02.
Therefore, in order to benchmark the ICRP 69 uranium systemic model, an f1 value of 0.02 was used.
Table 15 provides the committed dose equivalent from the Simulink model and the ICRP 69 literature
values.
Table 15: Committed Dose Equivalent for ICRP 69 uranium
systemic model
Committed Dose Equivalent ICRP 69 (Sv/Bq) for U-238
Bone Surface
Kidney
Liver

Simulink Model
6.75E-07
2.49E-07
9.37E-08

ICRP 69
7.10E-07
2.50E-07
9.60E-08

% Error
5.0
0.4
2.4

After each system was modeled in Simulink and benchmarked against the ICRP literature values for each
uranium isotope, both models combinations were used to make alterations and analyzed for all
gastrointestinal procedures.
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4.0 Development of Modified Anatomy Models
Radionuclides may enter the alimentary tract directly as a result of the ingestion or indirectly through
inhalation for a person with unmodified anatomy. However, when an ostomy patient enters the
workforce following the procedure, a potential new entrance point exists. This could lead to an
accidental injection of radioactive material through the stoma. To determine the potential impacts to
ostomies workers exposed to unsealed radioactive material, three pathways will be examined. The
pathways include ingestion, injection and stoma contamination or skin contamination. For this work,
injection refers to the entrance of material through the stoma, or hole created during a colostomy.

For this work, inhalation is not considered as a pathway. While inhalation is a main intake pathway,
inhalation is not considered due to the small fraction of material transferred to the GI tract. The small
fraction of material transferred to the GI tract would result in little to no change in dose estimates
compared to unmodified anatomy. If significant changes occur in the ingestion pathway, the
assumption can be re-examined.

When looking at the internal dose received by a worker it is important to consider the organs that the
ingested radionuclide passes through. For a normal healthy individual, the pathway would look similar
to that seen in Figure 1 or Figure 2, where the ingested radionuclide of concern would enter the mouth
and continue through the body from the stomach to the small intestine, small intestine to the large
intestine and though to excretion. The ICRP dosimetric model of the gastrointestinal tract discussed in
section 2 models this type of anatomy. However, in the case of an ostomy patient, this generic model
and must be modified to reflect the anatomical changes that occur. In each of the colostomy cases, the
ostomy will result in a truncated colon. Therefore, when implementing changes to the base model, a
new transfer coefficient will have to be determined. This is dependent on the length of the colon. In
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addition, for the ICRP 30 model, the mass of the content will have to be altered to reflect what is
present in the colon. It is assumed the content of the colon is uniformly distributed.

4.1 Adapting Models to Modified Anatomy
For a healthy person, the length of an individual’s colon may vary depending on gender and age.
Therefore, in order to use the models to simulate each gastrointestinal procedure, a few assumptions
had to be made about the gastrointestinal system. The lengths are based on the average colon lengths
for an adult human. The colon has a total length of 150 cm [18]. In addition, the following lengths of the
various sections of the colon are given; the ascending colon, 20 cm, the transverse colon, 45 cm,
descending colon, 30 cm, sigmoid colon, 45 cm, and the rectum, 10 cm [18].

ICRP 30 assumes the ULI consists of the ascending colon and the transverse colon. In addition, the LLI
consists of the descending colon, sigmoid colon, and rectum. Based on the listed lengths and the
predetermined section breakup listed from ICRP 30, the total length of the ULI and LLI were determined.
It was determined when using ICRP 30 GI tract model, that ULI had a total length of 65 cm and the LLI
had a total length of 85 cm. For the ULI this included adding the length of the ascending colon, 20 cm,
and the length of the transverse colon, 45 cm, to given 65 cm. In the case of the LLI this included adding
the length of the descending colon, 30 cm, the sigmoid colon, 45 cm, and the rectum, 10 cm.

ICRP 100 divides the colon into three sections instead of two. Therefore, the length of each
compartment, right colon, left colon, and rectosigmoid colon were determined. ICRP 100 assumes the
right colon consists of the ascending colon and the distal half of the transverse colon, the left colon
consists of the distal half of the transverse colon and the descending colon, and the rectosigmoid colon,
consist of the sigmoid colon and the rectum. Therefore, the base ICRP 100 HATM model assumed the
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right colon had a length of 42.5 cm. This was determined adding the ascending colon, 20 cm, and half
the transverse, 22.5 cm. The left colon was determined to have a total length of 52.5 cm. This was
determined by adding the length of the distal half of the transverse colon, 22.5 cm and the descending
colon, 30 cm. Finally, the rectosigmoid colon had a total length of 55 cm. This was determined by
adding the length of the sigmoid colon, 45 cm, and the rectum, 10 cm.

4.2 Transit Times
It was determined the change in dose to the colon was not sensitive to the location of the colostomy
and differed by less than 1%. Table displays the dose of a transverse colostomy at 25%, 50%, and 75% of
the transverse colon. Since 75% was the location used for dose calculation, the percent difference
between the dose from 75% was determined for 25% and 50%.
Table 16: CDE in the ULI for a transverse colostomy at various locations
Committed Dose Equivalent in the ULI for ICRP 30 for a Transverse Colon
Organ
ULI

Transverse
(75%)
1.451E-08

Transverse
(25%)
1.462E-08

% Difference
from 75%
0.76

Transverse
(50%)
1.46E-08

% Difference
from 75%
0.62

While in reality, each colostomy case is different and can be located at any point in the colon, for
purposes of this report, it was assumed that each procedure occurs at point halfway in the specified
section of the colon with the exception of the transverse colostomy. In order to represent the location
of the colostomy as accurately as possible, the transverse colostomy was assumed to be located at a
point 75% along the transverse colon. For example, in the case of the transverse colostomy, it was
assumed to occur at 75% of the transverse colon or based on the length, at 33.75 cm. With this
assumption, 17% of the ULI compartment would be removed as well as the LLI. Therefore, a transverse
colostomy results in 83% of the ULI compartment remaining after the procedure and the transfer
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coefficient was scaled to reflect the change. Table 16 displays the percentage of colon remaining for
each procedure for the ICRP 30 and ICRP 100 model.
Table 17: Percent colon remaining for each ostomy case for ICRP 30
and ICRP 100
Procedure

% Colon Remaining
ICRP 30

% Colon Remaining
ICRP 100

Ascending
Colostomy

ULI (16%)

RC (23.5%)

Transverse
Colostomy

ULI (83%)

LC (21%)

Descending
Colostomy

LLI (17.5%)

LC (71%)

Sigmoid
Colostomy

LLI (61.5%)

Rectosigmoid (41%)

Ileostomy

Small Intestine
(100%)

Small Intestine (100%)

Using the ICRP reported transfer coefficients, the lengths of the colon sections, and the location of the
colostomy, new transfer coefficients were determined for each gastrointestinal procedure. For example,
in the case of the transverse colostomy when applied to the ICRP 30 model, the new transfer coefficient
was determine by
𝜆𝑈𝐿𝐼 =

2.1𝑥10−5
0.83

= 2.57𝑥10−5

1
𝑠

(12)

Table 17 displays the new transfer coefficients calculated in reference to the ICRP 30 GI tract model for
each colostomy case and ICRP 30 literature values [1].

Table 18:Transfer Coefficients used to simulate each procedure in the ICRP 30 configuration model
Procedure
Transfer Coefficient (s-1)
ICRP 30 Transfer Coeffcient (s-1)
Ascending Colostomy
1.34x10-4
2.1x10-5
-5
Transverse Colostomy
2.57x10
2.1x10-5
Descending Colostomy
6.61x10-5
1.157x10-5
-5
Sigmoid Colostomy
1.887x10
1.157x10-5
-5
Ileostomy
6.9x10
6.9x10-5
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In the same manner, the transfer coefficients were calculated for each colostomy case for the use in the
ICRP 100 HATM model using the ICRP 100 transfer coefficients and the percent of remaining colon found
in Table 16. In the case of the transverse colostomy applied to ICRP 100 HATM, the transfer coefficient
does not change due to the division of sections in the model. The right colon consists of the proximal
half of the transverse colon, this including up to the location where the transverse colostomy occurs.
Table 18 displays the new transfer coefficients calculated for each colostomy procedure in reference to
the ICRP 100 HATM model as well as the literature ICRP 100 transfer coefficients [9].

Table 19: Transfer Coefficients used to simulate each procedure in the ICRP 100 configuration model
Procedure
Transfer Coefficient (s-1)
ICRP 100 Transfer Coefficient
2.381x10-5
1.013x10-4
Ascending colostomy
2.381x10-5
Transverse colostomy
1.066x10-4
-5
2.381x10-5
Descending colostomy
3.33x10
-5
2.381x10-5
Sigmoid colostomy
5.82x10
2.381x10-5
Ileostomy
6.9x10-5
4.3 Ingestion Pathway
Figure 14 displays an example of the modified ICRP 30 model to reflect a transverse colostomy.
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Figure 14: Block diagram representing the transfer between
compartments in the case of a transverse colostomy for the
ICRP 30 configuration
The radionuclide would follow the same pathway described in ICRP 30 model however, the transit time
in Table 17 would be applied to λULI to reflect a shortened ULI. In the case of the transverse colon, it was
determined that 65% of the ULI would remain following an ostomy. The contents would then excrete
into the bag application. The same procedure was applied to each ostomy case, in which the new
transfer coefficient was applied to the model to reflect the anatomical changes occurring for each and
the percentage of remaining colon found in Table 16. Figure 15 displays the transverse colostomy
applied to ICRP 100 HATM.
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Figure 15: Block diagram representing the transfer between
compartments in the case of a transverse colostomy for the ICRP
100 configuration
Like, ICRP 30, the radionuclide would follow the same pathway until it reaches the right colon in which
the transit time would be modified. λRC would be replaced by the new transfer coefficient found in Table
18. The same procedure can be applied for each ostomy case depending on the compartment in which
anatomical changes would occur, thus representing a shorter transit time due to a shortened colon. The
percentages found in Table 16 can be used to reflect the modified pathway in which the radionuclide
would follow for ingestion.
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4.4 Injection Pathway
The injection pathway assumed an activity of 1 Bq is instantaneously injected at t=0 through the stoma
into the intestine. It was assumed the radionuclide was uniformly distributed throughout the section of
the colon in which the injection occurred. Since it was assumed uniform distribution took place within
the colon section, the same transit times from Table 17 can be used in the ICRP 30 model. Figure 16
displays the schematic diagram of the injection pathway for the ICRP 30 model in the case of a
transverse colostomy.

ULI (83%)

Injection

Excretion

Figure 16: Injection pathway for a transverse colostomy for
the ICRP 30 model
The same procedure can be applied to each ostomy case depending on which section the colostomy
occurs. The transit times from Table 18 can be applied to the ICRP 100 HATM model to reflect the
anatomical changes made by each ostomy. Figure 17 displays the transverse colostomy applied to the
ICRP 100 HATM model.

44

Left Colon (21%)

Injection

Excretion

Figure 17: Schematic Diagram of the injection pathway for an
ileostomy applied to the ICRP 100 model
4.5 Stoma Contamination
As part of the injection pathway, contamination to the stoma was considered. Using a similar
methodology, the equation used by VARSKIN can be simplified and applied to the dose calculation for
contamination to the stoma. Equation 4 gives the beta dose. In general, skin dose resulting from an
alpha emitter is zero due to the layer of dead skin cell present. However, alpha dose must be
considered in contamination to the stoma due to the ability of the alpha particles to penetrate the colon
wall. The stoma consists of living tissue and does not have a layer of dead cells protecting it like skin
does. The equation used to calculate the beta and alpha dose to stoma is given by equation 13.

𝐷=

0.5 𝐸𝑌𝑖 𝑄𝐴𝐹
𝑚

(13)

Where:
E is the energy of the radiation
Y is the branching ratio
AF is the fraction of energy absorbed by the medium
m is the mass of the target
The mass of the target was determined using the continuous slowing down approximation range of the
alpha and beta particles. Assuming a 10 cm2 area of tissue, the relationship between CSDA and mass is
given by the following equation. 10 cm2 was considered based on regulations.
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𝑚 = 𝐶𝑆𝐷𝐴 𝑥 10 𝑐𝑚2

(14)

The CSDA for each alpha particle and beta particle was determined using tables provided by the National
Institute of Standards and Technology (NIST)[19]. In order to determine the energy dependent CSDA
from the tables provided by NIST, MATLAB was used to interpolate the energy specific values. This was
achieved by utilizing the interp1 function. MATLAB’s interp1 function is a 1-D data interpolation
function, which returns interpolated values at specific query points using linear interpolation [16]. It was
determined muscle provided the best CSDA estimate based on the biological properties of the colon and
small intestine. Unlike skin dose in which alpha particles would provide zero dose due to the inability of
the alpha particle to penetrate past the dead layer of cells, the colon does not provide shielding from
alpha particles. It was also assumed the mucosa layer did not provide any shielding from the alpha
particles. Therefore, they must be taken into consideration in the skin dose calculation. In order to
determine the dose to the colon from each uranium isotope, the alpha and beta dose was calculated for
each uranium isotope. The dose to the stoma was determined for an area of 10 cm2 based on
regulation. For example, using equation 5, the dose due to the 4.038 MeV alpha for 1 Bq of activity of
238

U was determined.

𝐷=

𝑀𝑒𝑉
𝐽
)1 𝐵𝑞 (1.6𝑥10−13
)(0.00078)(1)
𝑑𝑖𝑠
𝑀𝑒𝑉
𝑔
𝑘𝑔
2(0.0027 2 )(0.001 )(10 𝑐𝑚2 )
𝑔
𝑐𝑚

(4.038

𝐽

= 9.17𝑥10−12 𝑘𝑔 (𝐺𝑦)

(15)

Converting the dose from Gy to Sv per hour the equivalent dose per hour was determined.

𝐻=

9.17𝑥10−12 (20)
3600

𝑆𝑣

= 2.55𝑥10−15 ℎ𝑟

(16)

In the same manner, the equivalent dose was determined for each alpha particle emitted from 238U. The
result was then summed for all alpha particles emitted by the parent and if the parent included a shortlived daughter radionuclide, the radiation emitted by the daughter radionuclide was included. For
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example, the beta particles emitted by 231Th, the daughter radionuclide for 235U, were included in the
dose calculation because the half-life of 231Th is 25.5 hours. The same process was repeated for all alpha
particles and beta particles emitted for each specific uranium isotope, using the energy dependent
CSDA.
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5.0 Results
5.1 Ingestion Results ICRP 30 Model
Each combination, ICRP 30 GI tract model with ICRP 30 uranium systemic model and ICRP 100 HATM
model with ICRP 69 uranium systemic model, were used to evaluate the internal dose due to ingestion,
injection, and skin dose contamination for 233U, 234U, 235U, and 238U. In addition, for each isotope, the
new transfer coefficients and colon mass changes were applied to reflect the anatomical changes
present after an Ileostomy, ascending, transverse, descending, and sigmoid colostomy. Tables 19-22
display the internal dose calculated using ICRP 30 methodology for ingestion for 233U, 234U, 235U, and 238U,
respectively. The dash (-) indicated there was no dose to the organ.
Table 20: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake ingestion of 233U for each procedure case applied to the ICRP 30
configuration
Committed Dose Equivalent per Unit Intake Activity of U-233 Ingestion (Sv/Bq)
Organ
Stomach
Small Intestine
ULI
LLI
Bone Surface
Kidney
CEDE

Baseline
1.10E-09
2.75E-09
1.67E-08
4.88E-08
4.54E-08
1.85E-08
6.63E-09

Sigmoid
1.10E-09
2.75E-09
1.67E-08
4.87E-08
4.54E-08
1.85E-08
6.62E-09

Descending
1.10E-09
2.75E-09
1.67E-08
4.89E-08
4.54E-08
1.85E-08
6.63E-09

Transverse
1.10E-09
2.75E-09
1.63E-08
4.54E-08
1.85E-08
3.68E-09

Ascending
1.10E-09
2.75E-09
1.62E-08
4.54E-08
1.85E-08
3.67E-09

Ileostomy
1.10E-09
2.75E-09
4.54E-08
1.85E-08
2.70E-09

Table 21: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake ingestion of 234U for each procedure case applied to the ICRP 30
configuration
Committed Dose Equivalent per Unit Intake Activity of U-234 Ingestion (Sv/Bq)
Organ
Stomach
Small Intestine
ULI
LLI
Bone Surface
Kidney
CEDE

Baseline
1.09E-09
2.73E-09
1.66E-08
4.85E-08
4.51E-08
1.83E-08
6.59E-09

Sigmoid
1.09E-09
2.73E-09
1.66E-08
4.84E-08
4.51E-08
1.83E-08
6.58E-09

Descending
1.09E-09
2.73E-09
1.66E-08
4.86E-08
4.51E-08
1.83E-08
6.59E-09
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Transverse
1.09E-09
2.73E-09
1.62E-08
4.51E-08
1.83E-08
3.65E-09

Ascending
1.09E-09
2.73E-09
1.67E-08
4.51E-08
1.83E-08
3.68E-09

Ileostomy
1.09E-09
2.73E-09
4.51E-08
1.83E-08
2.68E-09

Table 22: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake ingestion of 235U for each procedure case applied to the ICRP 30
configuration
Committed Dose Equivalent per Unit Intake Activity of U-235 Ingestion (Sv/Bq)
Organ
Stomach
Small Intestine
ULI
LLI
Bone Surface
Kidney
CEDE

Baseline
1.12E-09
2.83E-09
1.72E-08
5.26E-08
4.15E-08
1.74E-08
6.71E-09

Sigmoid
1.12E-09
2.83E-09
1.72E-08
3.44E-08
4.15E-08
1.74E-08
5.62E-09

Descending
1.12E-09
2.83E-09
1.72E-08
1.21E-08
4.15E-08
1.74E-08
4.28E-09

Transverse
1.12E-09
2.83E-09
1.40E-08
4.15E-08
1.74E-08
3.36E-09

Ascending
1.12E-09
2.83E-09
2.99E-09
4.15E-08
1.74E-08
2.70E-09

Ileostomy
1.12E-09
2.83E-09
4.15E-08
1.74E-08
2.52E-09

Table 23: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake ingestion of 238U for each procedure case applied to the ICRP 30
configuration
Committed Dose Equivalent per Unit Intake Activity of U-238 Ingestion (Sv/Bq)
Organ
Stomach
Small Intestine
ULI
LLI
Bone Surface
Kidney
CEDE

Baseline
9.66E-10
2.42E-09
1.49E-08
4.48E-08
3.99E-08
1.62E-08
5.96E-09

Sigmoid
9.66E-10
2.42E-09
1.49E-08
4.44E-08
3.99E-08
1.62E-08
5.93E-09

Descending
9.66E-10
2.42E-09
1.49E-08
4.40E-08
3.99E-08
1.62E-08
5.90E-09

Transverse
9.66E-10
2.42E-09
1.45E-08
3.99E-08
1.62E-08
3.24E-09

Ascending
9.66E-10
2.42E-09
1.48E-08
3.99E-08
1.62E-08
3.26E-09

Ileostomy
9.66E-10
2.42E-09
3.99E-08
1.62E-08
2.37E-09

5.2 Ingestion Pathway ICRP 100 Model

Tables 23-26 display the committed equivalent dose calculated for each procedure for 233U, 234U, 235U,
and 238U using the ICRP 100 HATM and ICRP systemic system methodology. The tables also provide the
total body effective dose. The effective dose was calculated using two methods, ICRP 60 tissue
weighting factors and the ICRP 103 tissue weighting factors, found in Table 1. These provide the two
most up –to-date tissue weighting factors.
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Table 24: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake ingestion of 233U for each procedure case applied to the ICRP 100
configuration
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-233 Ingestion (Sv/Bq)
Organ
Bone
Liver
Kidney

Baseline
8.09E-08
1.13E-08
3.01E-08

Sigmoid
8.09E-08
1.13E-08
3.01E-08

Descending
8.09E-08
1.13E-08
3.01E-08

Transverse
8.09E-08
1.13E-08
3.01E-08

Ascending
8.09E-08
1.13E-08
3.01E-08

Ileostomy
8.09E-08
1.13E-08
3.01E-08

CEDE ICRP 60
CEDE ICRP 103

1.52E-09
1.54E-09

1.52E-09
1.54E-09

1.52E-09
1.54E-09

1.52E-09
1.54E-09

1.52E-09
1.54E-09

1.52E-09
1.54E-09

Table 25: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for
each target organ per unit intake ingestion of 234U for each procedure case applied to the ICRP 100
configuration
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-234 Ingestion (Sv/Bq)
Organ
Bone
Liver
Kidney

Baseline
8.03E-08
1.12E-08
2.99E-08

Sigmoid
8.03E-08
1.12E-08
2.99E-08

Descending
8.03E-08
1.12E-08
2.99E-08

Transverse
8.03E-08
1.12E-08
2.99E-08

Ascending
8.03E-08
1.12E-08
2.99E-08

Ileostomy
8.03E-08
1.12E-08
2.99E-08

CEDE ICRP 60
CEDE ICRP 103

1.51E-09
1.52E-09

1.51E-09
1.52E-09

1.51E-09
1.52E-09

1.51E-09
1.52E-09

1.51E-09
1.52E-09

1.51E-09
1.52E-09

Table 26: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake ingestion of 235U for each procedure case applied to the ICRP 100
configuration
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-235 Ingestion (Sv/Bq)
Organ
Oral Contents
Esophagus
Stomach
Small Intestine
Small Intestine Wall
Right Colon
Left Colon
Rectosigmoid
Bone
Liver
Kidney
CEDE ICRP 60
CEDE ICRP 103

Baseline
1.14E-17
6.27E-17
2.05E-14
4.08E-14
2.21E-14
2.68E-14
4.72E-14
2.07E-13
6.83E-08
9.48E-09
2.53E-08
1.28E-09
1.29E-09

Sigmoid
1.14E-17
6.27E-17
2.05E-14
4.08E-14
2.21E-14
2.68E-14
4.72E-14
1.86E-13
6.83E-08
9.48E-09
2.53E-08
1.28E-09
1.29E-09

Descending Transverse Ascending Ileostomy
1.14E-17
1.14E-17
1.14E-17
1.14E-17
6.27E-17
6.27E-17
6.27E-17
6.27E-17
2.05E-14
2.05E-14
2.05E-14
2.05E-14
4.08E-14
4.08E-14
4.08E-14
4.08E-14
2.21E-14
2.21E-14
2.21E-14
2.21E-14
2.68E-14
2.68E-14
1.49E-14
4.40E-14
1.89E-14
6.83E-08
6.83E-08
6.83E-08
6.83E-08
9.48E-09
9.48E-09
9.48E-09
9.48E-09
2.53E-08
2.53E-08
2.53E-08
2.53E-08
1.28E-09
1.28E-09
1.28E-09
1.28E-09
1.29E-09
1.29E-09
1.29E-09
1.29E-09
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Table 27: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake ingestion of 238U for each procedure case applied to the ICRP 100
configuration
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-238 Ingestion (Sv/Bq)
Organ
Oral Contents
Esophagus
Stomach
Small Intestine
Small Intestine Wall
Right Colon
Left Colon
Rectosigmoid
Bone
Liver
Kidney
CEDE ICRP 60
CEDE ICRP 103

Baseline
1.31E-17
7.19E-18
7.33E-15
2.77E-14
7.73E-15
3.21E-13
6.48E-13
3.24E-12
7.17E-08
9.96E-09
2.65E-08
1.35E-09
1.36E-09

Sigmoid Descending Transverse Ascending
1.31E-17
1.31E-17
1.31E-17
1.31E-17
7.19E-18
7.19E-18
7.19E-18
7.19E-18
7.33E-15
7.33E-15
7.33E-15
7.33E-15
2.77E-14
2.77E-14
2.77E-14
2.77E-14
7.73E-15
7.73E-15
7.73E-15
7.73E-15
3.21E-13
3.21E-13
3.21E-13
1.66E-13
6.48E-13
5.77E-13
2.32E-13
2.70E-12
7.17E-08
7.17E-08
7.17E-08
7.17E-08
9.96E-09
9.96E-09
9.96E-09
9.96E-09
2.65E-08
2.65E-08
2.65E-08
2.65E-08
1.35E-09
1.35E-09
1.35E-09
1.35E-09
1.36E-09
1.36E-09
1.36E-09
1.36E-09

Ileostomy
1.31E-17
7.19E-18
7.33E-15
2.77E-14
7.73E-15
7.17E-08
9.96E-09
2.65E-08
1.35E-09
1.36E-09

5.3 Injection Pathway ICRP 30 Model
Tables 27-30 provide the dose calculated using ICRP 30 methodology resulting from an injection through
the stoma for each procedure for 233U, 234U, 235U, and 238U. In addition, the each table lists the calculated
total body effective dose. The effective dose was calculated using ICRP 26 tissue weighting factors.
Table 28: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake injection of 233U for each procedure case applied to the ICRP 30
configuration
Committed Dose Equivalent and Committed Effective Dose per Unit Intake Activity of U-233
Injection (Sv/Bq)
Organ
Sigmoid
Descending
Transverse
Ascending
Ileostomy
Small Intestine
2.75E-09
ULI
1.63E-08
1.62E-08
LLI
4.88E-08
4.90E-08
Bone Surface
4.54E-08
Kidney
1.85E-08
CEDE
2.93E-09
2.94E-09
9.77E-10
9.73E-10
2.63E-09
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Table 29: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake injection of 234U for each procedure case applied to the ICRP 30
configuration
Committed Dose Equivalent and Committed Effective Dose per Unit Intake Activity of U-234
Injection (Sv/Bq)
Organ
Sigmoid
Descending
Transverse
Ascending
Ileostomy
Small Intestine
2.73E-09
ULI
1.62E-08
1.67E-08
LLI
4.85E-08
4.87E-08
Bone Surface
4.51E-08
Kidney
1.83E-08
CEDE
2.91E-09
2.92E-09
9.71E-10
1.00E-09
2.62E-09
Table 30: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake injection of 235U for each procedure case applied to the ICRP 30
configuration
Committed Dose Equivalent and Committed Effective Dose per Unit Intake Activity of U-235
Injection (Sv/Bq)
Organ
Sigmoid
Descending
Transverse
Ascending
Ileostomy
Small Intestine
2.82E-09
ULI
1.38E-08
2.66E-09
LLI
3.22E-08
9.37E-09
Bone Surface
4.15E-08
Kidney
1.74E-08
CEDE
1.93E-09
5.62E-10
8.25E-10
1.60E-10
2.46E-09
Table 31: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake injection of 238U for each procedure case applied to the ICRP 30
configuration
Committed Dose Equivalent and Committed Effective Dose per Unit Intake Activity of U-238
Injection (Sv/Bq)
Organ
Sigmoid
Descending
Transverse
Ascending
Ileostomy
Small Intestine
2.42E-09
ULI
1.45E-08
1.47E-08
LLI
4.36E-08
4.32E-08
Bone Surface
3.99E-08
Kidney
1.62E-08
CEDE
2.61E-09
2.59E-09
8.68E-10
8.84E-10
2.32E-09
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5.4 Injection Pathway ICRP 100 Model
Tables 31-32 provides the dose calculated due to injection of 235U and 238U. Under ICRP 100
methodology, no dose results to the colon from alpha particles. Therefore, 233U and 234U are not
included because they do have short lived daughter radionuclides that emit beta particles. For the
ileostomy, dose would result in the bone, liver, and kidney compartments but would be the same as if
ingested because the fraction of material transferred to the blood system remains the same. The tables
also provide the total body effective dose. The effective dose was calculated using two methods, ICRP 60
tissue weighting factors and the ICRP 103 tissue weighting factors.
Table 32:Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake injection of 235U for each procedure case applied to the ICRP 100
configuration
Committed Dose Equivalent and Committed Effective Dose per Unit Intake U-235 Injection (Sv/Bq)
Organ
Small Intestine
Small Intestine Wall
Right Colon
Left Colon
Rectosigmoid
Bone
Liver
Kidney

Sigmoid
3.89E-14
-

Descending
1.78E-14
-

Transverse
3.30E-15
-

Ascending
6.09E-15
-

Ileostomy
3.14E-14
2.06E-14
6.83E-08
9.48E-09
2.53E-08

CEDE ICRP 60
CEDE ICRP 103

1.56E-15
1.56E-15

7.14E-16
7.14E-16

7.74E-16
7.74E-16

2.43E-16
2.43E-16

1.28E-09
1.29E-09
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Table 33: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each
target organ per unit intake injection of 238U for each procedure case applied to the ICRP 100
configuration
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-238 Injection (Sv/Bq)
Organ
Small Intestine
Small Intestine Wall
Right Colon
Left Colon
Rectosigmoid
Bone
Liver
Kidney

Sigmoid
3.97E-13
-

Descending
1.94E-13
-

Transverse
3.14E-14
-

Ascending
5.77E-14
-

Ileostomy
2.13E-14
7.18E-15
7.17E-08
9.96E-09
2.65E-08

CEDE ICRP 60
CEDE ICRP 103

1.59E-14
1.59E-14

7.77E-15
7.77E-15

8.97E-15
8.97E-15

2.31E-15
2.31E-15

1.35E-09
1.36E-09

5.5 Annual Limit on Intake
To determine the potential risk to ostomy patients working with radioactive material, the annual limit
on intake was calculated for each uranium isotope and for each ostomy case. The ALI must be satisfied
by both the committed effective dose equivalent (CEDE) less than 0.05 Sv per year and the committed
dose equivalent (CDE) less than 0.5 Sv per year [1]. Therefore, the ALI is determined by the limiting
value. Tables 33-36 display the ALI’s for ingestion and injection for the ICRP 30 and ICRP 100 HATM
model configurations. The limiting organ is listed in the table where applicable, if the ALI is limited by
the CEDE, no organ is listed.
5.5.1 Annual Limit on Intake Ingestion
Table 34: Annual limit on intake (ALI) for ingestion using the ICRP 30 configuration in Bq
Base Model
Sigmoid
Descending Transverse Ascending Ileostomy
1.10E+07
1.10E+07
1.10E+07
U-233
7.54E+06
7.55E+06
7.54E+06
(Bone surf) (Bone surf) (Bone surf)
1.11E+07
1.11E+07
1.11E+07
U-234
7.59E+06
7.60E+06
7.58E+06
(Bone surf) (Bone surf) (Bone surf)
1.21E+07
1.21E+07
1.21E+07
U-235
7.45E+06
8.90E+06
1.17E+07
(Bone surf) (Bone surf) (Bone surf)
1.25E+07
1.25E+07
1.25E+07
U-238
8.39E+06
8.43E+06
8.47E+06
(Bone Surf) (Bone Surf) (Bone Surf)
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Table 35: Annual limit on intake (ALI) for ingestion using the ICRP 100 configuration in Bq
Base Model
Sigmoid
Descending Transverse Ascending
Ileostomy
6.18E+06
6.18E+06
6.18E+06
6.18E+06
6.18E+06
6.18E+06
U-233
(Bone surf) (Bone surf) (Bone surf) (Bone surf) (Bone surf) (Bone surf)
6.23E+06
6.23E+06
6.23E+06
6.23E+06
6.23E+06
6.23E+06
U-234
(Bone surf) (Bone surf) (Bone surf) (Bone surf) (Bone surf) (Bone surf)
7.32E+06
7.32E+06
7.32E+06
7.32E+06
7.32E+06
7.32E+06
U-235
(Bone surf) (Bone surf) (Bone surf) (Bone surf) (Bone surf) (Bone surf)
6.98E+06
6.98E+06
6.98E+06
6.98E+06
6.98E+06
6.98E+06
U-238
(Bone surf) (Bone surf) (Bone surf) (Bone surf) (Bone surf) (Bone surf)
5.5.2 Annual Limit on Intake Injection
Table 36: Annual limit on intake (ALI) for injection using the ICRP 30
configuration in Bq
Sigmoid
Descending Transverse Ascending
Ileostomy
1.02E+07
1.02E+07
3.07E+07
3.08E+07
1.10E+07
U-233
(LLI)
(LLI)
(ULI)
(ULI)
(Bone surf)
1.03E+07
1.03E+07
3.09E+07
3.00E+07
1.11E+07
U-234
(LLI)
(LLI)
(ULI)
(ULI)
(Bone surf)
1.55E+07
5.34E+07
3.64E+07
1.88E+08
1.21E+07
U-235
(LLI)
(LLI)
(ULI)
(ULI)
(Bone surf)
1.15E+07
1.16E+07
3.46E+07
3.39E+07
1.25E+07
U-238
(LLI)
(LLI)
(ULI)
(ULI)
(Bone surf)
Table 37: Annual limit on intake (ALI) for injection using the ICRP 100
configuration in Bq
Sigmoid Descending Transverse Ascending
Ileostomy
6.18E+06
U-233
(Bone surf)
6.23E+06
U-234
(Bone surf)
1.29E+13
2.80E+13
2.59E+13
8.21E+13
7.32E+06
U-235
(RS)
(LC)
(RC)
(RC)
(Bone surf)
1.26E+12
2.57E+12
2.23E+12
8.66E+12
6.98E+06
U-238
(RS)
(LC)
(RC)
(RC)
(Bone surf)
Based on Tables 33- 36, the ALI for each isotope and each case either remains the same as the
benchmarked case or has a greater ALI than the benchmarked case in the case of ingestion for both
model configurations. In the case of injection, for the ICRP 30 model configuration, the ALI for all
uranium isotopes are determined by the CDE which applies the dose of the limiting organ. All ALI for the
injection pathway are less than the ingestion pathway. The ICRP 100 model configuration results in the
55

same CEDE and CDE values for all cases. One exception is the ileostomy, which results in the same ALI as
the ingestion pathway and is limited by the CDE value.

5.6 Stoma Contamination Dose
Table 37 provides the dose per unit activity per hour in the event skin contamination occurs.
Table 38: Calculated skin dose in Sv per hour per
Bq for a 10 cm2 area for each uranium isotope
Dose per Bq per Hour per 10 cm2 (Sv per hour)
U-233
1.17E-10
U-234
6.03E-11
U-235
5.73E-11
U-238
6.42E-11
The values listed in Table 38 can be used to determine the dose to the colon dependent on the isotope
in order to further assess the contamination hazards. Table 39 displays dose to the stoma as a function
of contact time.
Table 39: Dose per Bq as a function of contact time for each uranium
isotope
Dose per Bq (Sv/Bq)
Time (min)
15
30
45
60
75
90
105
120

U-233
2.93E-11
5.86E-11
8.78E-11
1.17E-10
1.46E-10
1.76E-10
2.05E-10
2.34E-10

U-234
1.51E-11
3.02E-11
4.53E-11
6.03E-11
7.54E-11
9.05E-11
1.06E-10
1.21E-10

U-235
1.43E-11
2.86E-11
4.30E-11
5.73E-11
7.16E-11
8.59E-11
1.00E-10
1.15E-10

U-238
1.61E-11
3.21E-11
4.82E-11
6.42E-11
8.03E-11
9.63E-11
1.12E-10
1.28E-10

In addition, Table 39 displays the activity required to reach 10% of the annual limit to any organ of 0.5 Sv
per year in one hour.
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Table 40: Activity of uranium required to reach 10% of annual limit
in one hour
Dose Per hour (Sv per Bq per hour)
Activity (Bq)
U-233
U-234
U-235
U-238

1.17E-10
6.03E-11
5.73E-11
6.42E-11
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4.27E+08
8.29E+08
8.73E+08
7.78E+08

6.0 Discussion
As mentioned the chemical form of the radionuclide of concern may vary depending on the type of
exposure. For example, occupational exposures may result from specific inorganic forms of
radionuclides not present in the environment. It is important to note that the chemical form of the
radionuclide is likely changed during the digestive process [9]. These changes in chemical form will
determine the availability of the radionuclide for absorption and therefore the extent of uptake through
the intestinal epithelium to the bloodstream. As mentioned, this report will look at relatively insoluble
compounds with an f1 value of 0.002. By changing the f1 value to reflect a more soluble compound, the
fraction of material transferred to the blood system would increase leading to an increase in dose to the
organs within the systemic system but would not result in greater risk to the GI tract.

6.1 Ingestion Model 30
The dose resulting to each section of the colon does not significantly change regardless of an alteration
to the colon. In the case of a descending colostomy 233U and 234U the dose increases slightly from the
benchmarked case. This is not true of any other colostomy scenario where the dose decreases from the
unaltered case. This is not true for 235U and 238U where all committed dose equivalents are less than the
benchmarked case. However, while the committed dose equivalent increased slightly in the case of the
descending colostomy, it was determined to be insignificant, as it only differed from the unaltered case
by 0.16%. In addition, the slight increase in dose did not change the total body effective dose. The total
body effective dose is the same or less than the dose recorded for the benchmarked model. This is true
for all uranium isotopes analyzed. This is due to the slight increase in dose in the colon in which the
colostomy would take place for the sigmoid and descending colostomy as well as the dose to the LLI
being absent from the transverse and ascending colostomy. In addition, the CEDE for the ileostomy is
the lowest due to the radionuclide not passing through the ULI and LLI resulting in no dose for both
compartments.
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Table 41: CEDE doses for the ingestion using the ICRP 30 model configuration
Committed Effective Dose Equivalent for Ingestion Pathway
Base Model
6.63E-09
6.59E-09
6.71E-09
5.96E-09

U-233
U-234
U-235
U-238

Sigmoid
6.62E-09
6.58E-09
5.62E-09
5.93E-09

Descending Transverse Ascending Ileostomy
6.63E-09
3.68E-09
3.67E-09 2.70E-09
6.59E-09
3.65E-09
3.68E-09 2.68E-09
4.28E-09
3.36E-09
2.70E-09 2.52E-09
5.90E-09
3.24E-09
3.26E-09 2.37E-09

6.3 Injection Model 30
In the case of an injection, the recorded dose occurred within the section of the colon the injection
through the stoma would occur except in the case of the ileostomy. This is because transfer to the blood
system only occurs within the small intestine in the ICRP 30 model. Therefore, an injection outside the
region of the small intestine would result in no dose to the bone or kidney. Although transfer to the
blood would occur in the case of an ileostomy, the fraction of material transferred is the same as the
baseline model, f1= 0.002, and does not result in additional dose to the bone or kidney. From the tables,
the total body effective dose is less than the dose for a 1 Bq ingestion. Therefore, when looking at the
annual limit on intake, the ALI for the case of the injection would be greater than the ALI for ingestion of
the radionuclide.

Table 42: CEDE for the injection pathway using the ICRP 30 model
configuration
Committed Effective Dose Equivalent for Injection Pathway
U-233
U-234
U-235
U-238

Sigmoid
Descending Transverse Ascending Ileostomy
2.93E-09
2.94E-09
9.77E-10
9.73E-10 2.63E-09
2.91E-09
2.92E-09
9.71E-10
1.00E-09 2.62E-09
1.93E-09
5.62E-10
8.25E-10
1.60E-10 2.46E-09
2.61E-09
2.59E-09
8.68E-10
8.84E-10 2.32E-09
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6.2 Ingestion Model 100
When comparing the data for the ICRP 100 HATM and ICRP 69 systemic model combination, the
committed dose equivalent in the section of the colon in which the specific colostomy occurs is lower
than the benchmarked equivalent dose. In all cases, the dose to the bone, liver, and kidney remains
unchanged. This is due to the transfer value f1 not changing from the baseline model. While there is
retention in the small intestine wall the fraction transferred to the blood system remains the same. Due
to the way the absorbed fractions are handled for alpha particles in the alimentary tract in ICRP 100,
alpha dose is negligible in the colon due to the location of the cancer inducing cells. The cancer
susceptible cells are located at a depth beyond the penetration depth of the alpha particle. This results
in a significantly lower dose equivalent in the ICRP 100 HATM model than ICRP 30. This is especially
apparent in the cases of 233U and 234U. The dose to all sections of the colon is negligible and the only
recorded dose results from the transfer of material to the organs within the systemic system. In the
other case of 235U and 238U, the dose in the colon is due purely to the beta emissions from the daughter
isotopes.

Due to the low equivalent doses in the alimentary tract and the most significant dose occurring in the
bone compartment for uranium, the committed effective dose equivalent does not change for each
procedure for each isotope. In addition, there is no significant difference in the total body effective dose
when using the ICRP 60 methodology versus the ICRP 103 methodology. Table 42 displays the CEDE
using ICRP 103 methodology because they are more conservative than the ICRP 60.
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Table 43: CEDE values for ingestions using the ICRP 100 model configuration
Committed Effective Dose Equivalent for Ingestion
U-233
U-234
U-235
U-238

Base Model Sigmoid
Descending Transverse Ascending Ileostomy
1.54E-09 1.54E-09
1.54E-09
1.54E-09
1.54E-09 1.54E-09
1.52E-09 1.52E-09
1.52E-09
1.52E-09
1.52E-09 1.52E-09
1.29E-09 1.29E-09
1.29E-09
1.29E-09
1.29E-09 1.29E-09
1.36E-09 1.36E-09
1.36E-09
1.36E-09
1.36E-09 1.36E-09

6.4 Injection Model 100
Finally, when looking at the injection pathway, the resulting total body effective dose is significantly
lower than the ingestion pathway with the exception of the ileostomy in which the effective dose is
consistent with the ingestion pathway. This is due to the transfer of material to the blood system from
the small intestine and no transfer from additional compartments in the alimentary tract for uranium. In
all other cases, the material would enter the colon through the stoma and transfer out in the same
manner as the ingestion pathway thus, resulting in no transfer to the blood system. The injection
pathway was insignificant for 233U and 234U due to each isotope and daughter emitting only alpha
particles. The only dose that would result is the dose due to transfer through the blood system but
would not be increased from the ingestion case due to the constant transfer fraction.
Table 44: CEDE values for the injection pathway using ICRP 100
Committed Effective Dose for Injection
U-235
U-238

Sigmoid
Descending Transverse Ascending Ileostomy
1.56E-15
7.14E-16
7.74E-16
2.43E-16 1.29E-09
1.59E-14
7.77E-15
8.97E-15
2.31E-15 1.36E-09

6.6 Stoma Dose
The major question regarding skin contamination is what level of activity would prompt medical
intervention. The decision should ultimately be left up to the treating physician but the decision should
take dosimetry into consideration. No definitive guidance exists, as every case is different [20]. The
intervention required may range from washing the contaminated area to surgical excision. The NCRP
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report suggests intervention when the dose to the skin exceeds one to ten times the annual limit [20].
Doses to the stoma can be calculated using Table 37. The first step in any contamination case is
decontamination, removing any visible fragments and irrigation using a saline solution followed by
assessment of remaining activity using an appropriate detector [20]. Soap and water may also be used in
decontaminating the stoma and surrounding area. Any required additional action may want to be
performed by a medical professional . While it is important to consult a health physicist, based on the
length of time required to reach a dose level of concern or the level of activity that would have to
present, the chemical hazard of the contaminant would be of greater concern than the radiological
concerns of uranium.

6.7 Conclusions
Both the ICRP 30 gastrointestinal tract connected to the ICRP 30 uranium systemic model and the ICRP
100 HATM and ICRP 69 uranium systemic model resulted in the same conclusion for ingestion. The
equivalent dose in the affected colon was reduced below the benchmarked value. This in turn, led to a
reduced overall total effective dose for the ICRP 30 model for a transverse or ascending colostomy, and
in the case of an ileostomy. The total effective dose remained the same in the case of a sigmoid or
descending colostomy. Table 44 displays the CEDE values determined from the ingestion pathway for
the ICRP 30 model.
Table 45: CEDE values for the ingestion pathway using ICRP 30 model for each uranium
isotope
Committed Effective Dose Equivalent for Ingestion Pathway
Base Model
U-233

6.63E-09

U-234

6.59E-09

U-235

6.71E-09

U-238

5.96E-09

Sigmoid
6.62E09
6.58E09
5.62E09
5.93E09

Descending Transverse Ascending Ileostomy
6.63E-09

3.68E-09

3.67E-09

2.70E-09

6.59E-09

3.65E-09

3.68E-09

2.68E-09

4.28E-09

3.36E-09

2.70E-09

2.52E-09

5.90E-09

3.24E-09

3.26E-09

2.37E-09
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Due to the change in tissue weighting factors for the ICRP 60 and ICRP 103, the total effective dose
remained the same in the ICRP 100 combination regardless of whether the colon was anatomically
changed due to a colostomy or not. This is because the ALI is determined by the greatest intake of a
radionuclide that satisfies a total effective dose less than 0.05 Sv or a committed dose equivalent less
than 0.5 Sv. In the case of ICRP 100 the bone is the limiting organ and since the dose does not change,
the ALI remains constant. In addition, the ALI is the lowest in the baseline case for the ICRP 30
combination and does not change in the case of the ICRP 100 combination..

Based on the data, the injection pathway does not pose an additional risk to an occupational worker in
regard to uranium. The ALI calculated for injection is equivalent or orders of magnitude greater than the
ingestion pathway. Therefore, it does not require additional limits on the amount of activity in use. Since
the small intestine is the only section in which a fraction of material is transferred the systemic system,
the ileostomy is the only scenario in which material can be passed to the blood for both model
combinations. This resulted in no additional dose to any section in the gastrointestinal tract or systemic
system. Finally, when looking at the ALI for all cases of injection for the ICRP 30 model combination, the
ALI is greater than the baseline case for all colostomies except the Ileostomy. In the case of the
Ileostomy, the ALI is the same as the ingestion pathway.

Due to the unique pathway, there is no base model or ICRP reported ALI’s for the injection pathway.
However, the ALI for all cases of injection for the ICRP 100 combination is significantly greater than the
base model ingestion pathway in all cases except for the ileostomy, which is the same as the ingestion
case. Therefore, due to a decrease in equivalent doses and an increase in ALI’s, no additional
precautions need to be taken in the event a worker enters the workforce with a colostomy when
considering injection as an individual pathway.
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Due to the possibility of the adhesion on the bag application becoming loose over time there is a
possibility for the appliance to become dislodged, leading to the possibility of stoma contamination.
Stoma contamination is also necessary in the event injection occurs. Although the dose per hour does
not appear to be significant, alpha particles can penetrate the wall of the intestine due to the lack of
shielding. Therefore, the potential dose to the skin of the intestine should be taken into account.
However, when looking at the skin dose due to each uranium isotope, the dose received to the stoma
per hour is low. Furthermore, the activity required to reach 10% of the annual limit in one hour is on the
order of 108 Bq. Oftentimes, uranium is dissolved in an acid solution like nitric or sulfuric acid. Therefore,
due to low dose rate, the chemical hazards would be of more concern than the radiological risks.

Taking into account all three potential pathways, ingestion, injection, and stoma contamination; there is
no additional risk to an ostomy patient working with uranium. Furthermore, additional precautions do
not need to be taken for an ostomy patient working with uranium. This means additional guidance is not
necessary for ostomy patients to reduce potential exposure. In addition, if contamination of the stoma
does occur, the chemical hazards are a greater concern than the radiological hazards.

6.7 Future Work
This work focused on uranium as it is commonly used for actinide research. With the base models built
for each ICRP biokinetic model, the research can be expanded in a number of ways. The systemic model
designed by Leggett and published in ICRP 69 is the base model for all actinides. This is due to the
similarity in biological behavior of actinides once incorporated inside the body. In order to apply the
model to other actinides, the transfer coefficients are element specific and would need to be updated
for the specific radionuclide. This research focused on different uranium isotopes and the transfer
values were specific to the uranium. In order to get a better look at the effects a gastrointestinal tract
operation that alters the standard anatomy may have on internal dosimetry, other radionuclides
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commonly used should be looked at. This could include the other actinides such as plutonium, thorium,
and americium. Skin contamination may be of greater risk for a gamma emitter like 137Cs. It may also
include radionuclides with unique transfer to the blood system from areas in the alimentary tract other
than the small intestine. For example, there is some evidence to suggest iodine is absorbed in the
stomach. While uranium gave a good indication that no additional restrictions should be placed on an
individual with a colostomy who has reentered the workforce, it should not be assumed this is true for
all radionuclides. Therefore, it would be beneficial to look at other radionuclides. In particular, the other
actinides would be a simple addition, as it would require minimal changes to the already existing models
but would provide a better understanding about the effects.

In addition, ICRP plans to publish updated dose coefficients for uranium and therefore, in the future will
allow the ICRP 100 HATM model to be benchmarked against the literature values. With the publication
of 130, ICRP also plans to include updated bone dosimetry [1]. Both the ICRP 30 and ICRP 69 systemic
model used ICRP 30 methodology for calculation of bone equivalent dose as it is currently the only
methodology for bone dosimetry. With the updated methodology, the model can be updated with the
new methodology for bone dosimetry. With the new updated bone dosimetry and uranium dose
coefficients, the model would have to be benchmarked against the updated values. This will provide the
most up to date calculation for the dose to bone. This is especially important for uranium, as the bone is
the limiting dose. While, this will not change the outcome of the research due to the transfer of material
to the blood system being constant, it will allow for the most up to date dose calculation for bone. In
addition, with the ability to benchmark the model against published ICRP 130 values for uranium in the
GI tract, it will also ensure the dose to the alimentary tract is up to date.
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